TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Argenica Therapeutics Ltd ( (AU:AGN) ) just unveiled an update.
Argenica Therapeutics announced the retirement of Mr. Terry Budge, a non-executive director, at the conclusion of their AGM. Mr. Budge has been a pivotal figure since January 2021, contributing significantly to the company’s IPO and the development of ARG-007. His leadership in financial stewardship and capital raising has been instrumental in advancing the company’s clinical trials and development efforts. The company expressed gratitude for his dedication and support.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Limited is a biotechnology company focused on developing novel therapeutics aimed at reducing brain tissue death following strokes and other neurological conditions. Their lead product, ARG-007, is a neuroprotective peptide that has shown promising results in pre-clinical models and has undergone Phase 1 and Phase 2 clinical trials to assess its safety and efficacy.
Average Trading Volume: 586,727
Technical Sentiment Signal: Sell
For an in-depth examination of AGN stock, go to TipRanks’ Overview page.